MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M |
| Total Depreciation and Amortization | 64.00K | 160.00K | 50.00K | 61.00K | 77.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.94M | 2.03M | 1.54M | 998.00K | 525.00K |
| Change in Net Operating Assets | -1.69M | 1.57M | -1.51M | 918.00K | 600.00K |
| Cash from Operations | -20.21M | -18.30M | -21.54M | -17.43M | -22.68M |
| Capital Expenditure | -437.00K | -793.00K | -399.00K | -707.00K | -30.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.66M | -129.18M | 17.46M | 26.69M | 3.26M |
| Cash from Investing | -97.10M | -129.97M | 17.06M | 25.99M | 3.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 87.81M | 955.00K | 188.08M | 1.33M | 4.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -378.00K | -517.00K | -254.00K | -- | -- |
| Cash from Financing | 87.44M | 438.00K | 187.82M | 1.33M | 4.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.87M | -147.84M | 183.34M | 9.88M | -19.45M |